Lexicon Pharmaceuticals, Inc. announced that a post hoc analysis of clinical data from the SCORED trial demonstrated that clinical benefit from INPEFA® use in heart failure and major adverse cardiovascular events related outcomes was observed as early as approximately three months in patients at high risk for cardiovascular events.
